Trial Profile
An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Sep 2023 Status changed from active, no longer recruiting to completed.
- 07 Dec 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 07 Dec 2022 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.